Novartis decides not to pursue further development of Aurograb(TM)

in
  • Aurograb(TM) decision reached after Phase II results show lack of efficacy as an add -on therapy for life-threatening bacterial infections



  • USD 235 million impairment charge to be taken in 2008 third quarter results



  • Mycograb(TM) continues in Phase III trials for treatment of severe fungal infections